Association between pharmacologic treatment and hospital utilization at birth among neonatal opioid withdrawal syndrome mother-infant dyads.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
30
08
2022
accepted:
23
01
2023
revised:
19
01
2023
pubmed:
31
1
2023
medline:
10
3
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
We linked mother-baby dyads to explore associations between maternal medication-assisted therapy (MAT) and infants' pharmacologic treatment on birth hospital utilization for infants with NOWS. We extracted singleton infant and maternal delivery discharges from PHIS hospitals with large volumes of deliveries for 2016-2019. We matched newborns with NOWS to maternal delivery discharges by hospital, day of birth, mode of delivery, and ZIP code. We examined the association between maternal MAT, infants' pharmacologic treatment, and hospital utilization at birth. We included N = 146 mother-baby dyads from six hospitals (74% match rate). Among matched dyads, 51% received maternal MAT, 60% pharmacotherapy (37% both). Infants treated non-pharmacologically and born to mothers receiving MAT had the shortest stays vs. infants without pharmacotherapy or MAT (RR = 0.29; 95% CI: 0.25-0.35). These findings underscore the importance of adequate perinatal treatment for opioid use disorder to improve outcomes for mothers and infants with opioid exposure.
Identifiants
pubmed: 36717607
doi: 10.1038/s41372-023-01623-6
pii: 10.1038/s41372-023-01623-6
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-292Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120:1216–24.
pubmed: 24525628
doi: 10.1097/ALN.0000000000000172
Brown JD, Doshi PA, Pauly NJ, Talbert JC. Rates of neonatal abstinence syndrome amid efforts to combat the opioid abuse epidemic. JAMA Pediatr. 2016;170:1110–2.
pubmed: 27669331
pmcid: 5444666
doi: 10.1001/jamapediatrics.2016.2150
Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35:650–5.
pubmed: 25927272
pmcid: 4520760
doi: 10.1038/jp.2015.36
Pryor JR, Maalouf FI, Krans EE, Schumacher RE, Cooper WO, Patrick SW. The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. Arch Dis Child Fetal Neonatal Ed. 2017;102:F183–F7.
pubmed: 28073819
doi: 10.1136/archdischild-2015-310045
Villapiano NL, Winkelman TN, Kozhimannil KB, Davis MM, Patrick SW. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013. JAMA Pediatr. 2017;171:194–6.
pubmed: 27942711
doi: 10.1001/jamapediatrics.2016.3750
Wachman EM, Grossman M, Schiff DM, Philipp BL, Minear S, Hutton E, et al. Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome. J Perinatol. 2018;38:1114–22.
pubmed: 29740196
doi: 10.1038/s41372-018-0109-8
Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children’s hospitals, 2004-2011. J Perinatol. 2014;34:867–72.
pubmed: 24921412
doi: 10.1038/jp.2014.114
Abrahams RR, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician. 2007;53:1723–30.
Holmes AV, Atwood EC, Whalen B, Beliveau J, Jarvis JD, Matulis JC, et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics. 2016;137:e20152929.
Grossman MR, Berkwitt AK, Osborn RR, Xu Y, Esserman DA, Shapiro ED, et al. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics. 2017;139:e20163360.
Grossman MR, Osborn RR, Berkwitt AK. Neonatal abstinence syndrome: time for a reappraisal. Hosp Pediatr. 2017;7:115–6.
pubmed: 28137921
doi: 10.1542/hpeds.2016-0119
MacMillan KDL. Neonatal abstinence syndrome: review of epidemiology, care models, and current understanding of outcomes. Clin Perinatol. 2019;46:817–32.
pubmed: 31653310
doi: 10.1016/j.clp.2019.08.012
Singh R, Houghton M, Melvin P, Wachman EM, Diop H, Iverson R, Jr., et al. Predictors of pharmacologic therapy for neonatal opioid withdrawal syndrome: a retrospective analysis of a statewide database. J Perinatol. 2021;41:1381–8.
Patrick SW, Barfield WD, Poindexter BB, Committee On Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. Pediatrics. 2020;146:e2020029074.
Howard MB, Schiff DM, Penwill N, Si W, Rai A, Wolfgang T, et al. Impact of parental presence at infants’ bedside on neonatal abstinence syndrome. Hosp Pediatr. 2017;7:63–9.
pubmed: 28137920
doi: 10.1542/hpeds.2016-0147
Wachman EM, Houghton M, Melvin P, Isley BC, Murzycki J, Singh R, et al. A quality improvement initiative to implement the eat, sleep, console neonatal opioid withdrawal syndrome care tool in Massachusetts’ PNQIN collaborative. J Perinatol. 2020;40:1560–9.
pubmed: 32678314
doi: 10.1038/s41372-020-0733-y
Grisham LM, Stephen MM, Coykendall MR, Kane MF, Maurer JA, Bader MY. Eat, sleep, console approach: a family-centered model for the treatment of neonatal abstinence syndrome. Adv Neonatal Care. 2019;19:138–44.
pubmed: 30855311
doi: 10.1097/ANC.0000000000000581
Blount T, Painter A, Freeman E, Grossman M, Sutton AG. Reduction in length of stay and morphine use for NAS With the “Eat, Sleep, Console” Method. Hosp Pediatr. 2019;9:615–23.
pubmed: 31285356
doi: 10.1542/hpeds.2018-0238
Milliren CE, Gupta M, Graham DA, Melvin P, Jorina M, Ozonoff A. Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2016. Hosp Pediatr. 2018;8:15–20.
pubmed: 29263122
doi: 10.1542/hpeds.2017-0077
Bogen DL, Whalen BL, Kair LR, Vining M, King BA. Wide variation found in care of opioid-exposed newborns. Acad Pediatr. 2017;17:374–80.
pubmed: 27889436
doi: 10.1016/j.acap.2016.10.003
Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019;94:2072–86.
pubmed: 31543255
doi: 10.1016/j.mayocp.2019.03.029
Jones HE, Chisolm MS, Jansson LM, Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction. 2013;108:233–47.
pubmed: 22471668
doi: 10.1111/j.1360-0443.2012.03811.x
American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130:e81–94.
doi: 10.1097/AOG.0000000000002235
Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. Rockville, MD; 2018. Contract No.: HHS Publication No. (SMA) 18-5054.
Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125:363–8.
pubmed: 25569005
doi: 10.1097/AOG.0000000000000640
Towers CV, Hyatt BW, Visconti KC, Chernicky L, Chattin K, Fortner KB. Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics. 2019;143:e20180541.
Coulson CC, Lorencz E, Rittenhouse K, Ramage M, Lorenz K, Galvin SL. Association of maternal buprenorphine or methadone dose with fetal growth indices and neonatal abstinence syndrome. Am J Perinatol. 2021;38:28–36.
pubmed: 31421639
doi: 10.1055/s-0039-1694729
Ramage M, Ostrach B, Fagan B, Coulson CC. Stabilizing the mother-infant dyad for better outcomes from OB to FM: Caring for patients with perinatal opioid use disorder through the 4th trimester. North Carol Med J. 2018;79:164–5.
doi: 10.18043/ncm.79.3.164
Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol. 2015;39:561–5.
pubmed: 26452318
pmcid: 4628571
doi: 10.1053/j.semperi.2015.08.013
Scott LF, Guilfoy V, Duwve JM, Rawl SM, Cleveland L. Factors associated with the need for pharmacological management of neonatal opioid withdrawal syndrome. Adv Neonatal Care. 2020;20:364–73.
pubmed: 32868586
doi: 10.1097/ANC.0000000000000772
Honein MA, Boyle C, Redfield RR. Public health surveillance of prenatal opioid exposure in mothers and infants. Pediatrics. 2019;143:e20183801.
Hahn PD, Melvin P, Graham DA, Milliren CE. A methodology to create mother-baby dyads using data from the Pediatric Health Information System. Hosp Pediatr. 2022;12:884–92.
Milliren CE, Melvin P, Ozonoff A. Pediatric hospital readmissions for infants with neonatal opioid withdrawal syndrome, 2016–2019. Hosp Pediatr. 2021;11:979–87.
pubmed: 34417200
doi: 10.1542/hpeds.2021-005904
Keren R, Luan X, Localio R, Hall M, McLeod L, Dai D, et al. Prioritization of comparative effectiveness research topics in hospital pediatrics. Arch Pediatr Adolesc Med. 2012;166:1155–64.
pubmed: 23027409
doi: 10.1001/archpediatrics.2012.1266
Jonas JA, Shah SS, Zaniletti I, Hall M, Colvin JD, Gottlieb LM, et al. Regional variation in standardized costs of care at children’s hospitals. J Hosp Med. 2017;12:818–25.
pubmed: 28991947
doi: 10.12788/jhm.2829
Congressional Budget Office. The Distribution of Household Income, 2016. 2019. https://www.cbo.gov/publication/55413 .
Ton TG, Bennett MV, Incerti D, Peneva D, Druzin M, Stevens W, et al. Maternal and infant adverse outcomes associated with mild and severe preeclampsia during the first year after delivery in the United States. Am J Perinatol. 2020;37:398–408.
pubmed: 30780187
doi: 10.1055/s-0039-1679916
Blake HA, Sharples LD, Harron K, van der Meulen JH, Walker K. Probabilistic linkage without personal information successfully linked national clinical datasets. J Clin Epidemiol. 2021;136:136–45.
pubmed: 33932483
pmcid: 8443839
doi: 10.1016/j.jclinepi.2021.04.015
Johnson KE, Beaton SJ, Andrade SE, Cheetham TC, Scott PE, Hammad TA, et al. Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes. Pharmacoepidemiol Drug Saf. 2013;22:776–82.
pubmed: 23596095
pmcid: 3707923
doi: 10.1002/pds.3443
Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298.
Clark RRS, French R, Lorch S, O’Rourke K, Rosenbaum KEF, Lake ET. Within-hospital concordance of opioid exposure diagnosis coding in mothers and newborns. Hosp Pediatr. 2021;11:825–33.
pubmed: 34230061
pmcid: 8336457
doi: 10.1542/hpeds.2020-003863
Goyal S, Saunders KC, Moore CS, Fillo KT, Ko JY, Manning SE, et al. Identification of substance-exposed newborns and neonatal abstinence syndrome using ICD-10-CM—15 hospitals, Massachusetts, 2017. Morb Mortal Wkly Rep. 2020;69:951.
doi: 10.15585/mmwr.mm6929a2
Maalouf FI, Cooper WO, Stratton SM, Dudley JA, Ko J, Banerji A, et al. Positive predictive value of administrative data for neonatal abstinence syndrome. Pediatrics. 2019;143: e20174183.
Peeler M, Gupta M, Melvin P, Bryant AS, Diop H, Iverson R, et al. Racial and ethnic disparities in maternal and infant outcomes among opioid-exposed mother-infant dyads in Massachusetts (2017–2019). Am J Public Health. 2020;110:1828–36.
pubmed: 33058701
pmcid: 7661985
doi: 10.2105/AJPH.2020.305888
Schiff DM, Nielsen T, Hoeppner BB, Terplan M, Hansen H, Bernson D, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Netw Open. 2020;3:e205734.
pubmed: 32453384
pmcid: 7251447
doi: 10.1001/jamanetworkopen.2020.5734
Guerrero EG, Marsh JC, Duan L, Oh C, Perron B, Lee B. Disparities in completion of substance abuse treatment between and within racial and ethnic groups. Health Serv Res. 2013;48:1450–67.
pubmed: 23350871
pmcid: 3725534
doi: 10.1111/1475-6773.12031
Cook BL, Alegria M. Racial-ethnic disparities in substance abuse treatment: the role of criminal history and socioeconomic status. Psychiatr Serv. 2011;62:1273–81.
pubmed: 22211205
pmcid: 3665009
doi: 10.1176/ps.62.11.pss6211_1273
Pinedo M. A current re-examination of racial/ethnic disparities in the use of substance abuse treatment: Do disparities persist? Drug Alcohol Depend. 2019;202:162–7.
pubmed: 31352305
doi: 10.1016/j.drugalcdep.2019.05.017
Elmore AL, Tanner JP, Lowry J, Lake-Burger H, Kirby RS, Hudak ML, et al. Diagnosis codes and case definitions for neonatal abstinence syndrome. Pediatrics. 2020;146:e20200567.
Wen T, Batista N, Wright JD, D’Alton ME, Attenello FJ, Mack WJ, et al. Postpartum readmissions among women with opioid use disorder. Am J Obstet Gynecol MFM. 2019;1:89–98.
pubmed: 33319760
doi: 10.1016/j.ajogmf.2019.02.004
Patrick SW, Burke JF, Biel TJ, Auger KA, Goyal NK, Cooper WO. Risk of hospital readmission among infants with neonatal abstinence syndrome. Hosp Pediatr. 2015;5:513–9.
pubmed: 26427919
pmcid: 5110214
doi: 10.1542/hpeds.2015-0024
Shrestha S, Roberts MH, Maxwell JR, Leeman LM, Bakhireva LN. Post-discharge healthcare utilization in infants with neonatal opioid withdrawal syndrome. Neurotoxicol Teratol. 2021;86:106975.
pubmed: 33766722
pmcid: 8277706
doi: 10.1016/j.ntt.2021.106975
Hwang SS, Liu CL, Yu Q, Cui X, Diop H. Risk factors for emergency room use and rehospitalization among opioid-exposed newborns in Massachusetts. Birth. 2021;48:26–35.
pubmed: 32888362
doi: 10.1111/birt.12502
Lappen JR, Stark S, Bailit JL, Gibson KS. Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome. Am J Obstet Gynecol MFM. 2020;2:100075.
pubmed: 33345989
doi: 10.1016/j.ajogmf.2019.100075